ESMO

Cancer Data from European Conference May Lead to FDA Approvals

October 30th 2023, 2:00pm

Podcast

CURE® editors discuss data from the European Society of Medical Oncology Annual Congress, and how it could lead to new therapies being approved.

Jemperli Plus Chemo Continues to Demonstrate Strong Outcomes in Advanced NSCLC

October 29th 2023, 4:00pm

Article

Jemperli plus chemotherapy demonstrated improvement in overall survival compared with Keytruda and chemotherapy in patients with treatment-naïve, nonsquamous non–small cell lung cancer.

Tecentriq and Zejula Plus Chemo Did Not Offer Better Outcomes in Recurrent Ovarian Cancer

October 29th 2023, 1:00pm

Article

Treatment with Tecentriq plus Zejula and chemotherapy did not offer better outcomes to patients with recurrent ovarian cancer, according to results from a phase 3 trial.

Libtayo Shows Survival Benefit In CSCC After Year Follow Up

October 28th 2023, 7:00pm

Article

A recent phase 2 study showed promising survival improvements with neoadjuvant Libtayo in patients with cutaneous squamous cell carcinoma after a year and a half follow up.

Keytruda Plus Herceptin, Chemo Boosts PFS in HER2+ Gastric/GEJ Cancer

October 28th 2023, 5:00pm

Article

Keytruda plus the combination of Herceptin and chemotherapy led to an improvement in progression-free survival versus placebo plus Herceptin and chemotherapy in the first-line treatment of some patients with metastatic HER2-positive gastric or gastroesophageal junction cancer.

Pluvicto Plus Xtandi Enhances Anti-Tumor Activity for Some Patients With Prostate Cancer

October 27th 2023, 9:00pm

Article

Data presented at ESMO “provides strong evidence for an enhanced anti-cancer effect with the combination” of Pluvicto and Xtandi, according to one expert.

Imfinzi-Chemo Combo Shows Promise in Ongoing Gastric Cancer Trial

October 27th 2023, 1:00pm

Article

The addition of Imfinzi to a chemotherapy regimen called FLOT tended to boost pathologic complete response rates in patients with gastric or gastroesophageal junction cancer.

Keytruda Plus Chemo Improves Progression-Free Survival in Cervical Cancer

October 25th 2023, 10:00pm

Article

The addition of Keytruda to external beam radiotherapy and concurrent chemotherapy, followed by brachytherapy, resulted in statistically significant and clinically meaningful improvements in progression-free survival in patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer.

Verzenio, Endocrine Therapy Boosts Outcomes in High-Risk Breast Cancer

October 25th 2023, 3:00pm

Article

Patients with HR-positive, HER2-negative high-risk early breast cancer tended to experience improved invasive disease and distant relapse-free survival after adding Verzenio to endocrine therapy.

Cabometyx Improves Survival Without Progression in Previously Treated Advanced NETs

October 24th 2023, 11:00pm

Article

Patients with previously treated advanced neuroendocrine tumors who received treatment with Cabometyx had improved progression-free survival compared with placebo.